
‘Ozempic mouth' and ‘Ozempic teeth' can be frightening — here's the No. 1 way to protect your smile
GLP-1 drugs like Ozempic and Mounjaro can be a wild ride — users may experience dramatic weight loss and a sharp drop in appetite but also fierce bouts of nausea, vomiting or diarrhea.
There's one possible complication that shouldn't be brushed off. GLP-1 meds, which promote feelings of fullness by mimicking a naturally occurring hormone, can significantly impact oral health.
This phenomenon is known as 'Ozempic mouth' or 'Ozempic teeth.'
5 Dr. Elizabeth Walton of Risas Kids Dental in Phoenix reveals how to prevent 'Ozempic mouth' and 'Ozempic teeth.'
Courtesy of Risas Kids Dental
'Much of this revolves around the side effect of dry mouth,' Dr. Elizabeth Walton, co-founder and clinical director of Risas Kids Dental in Phoenix, told The Post.
'With dry mouth, you have increased likelihood of dental decay and periodontal disease.'
Walton fills us in on ways that Ozempic-like drugs can menace the mouth — and how to get to the root of the issue.
Saliva takes a lickin'
Saliva neutralizes acid, washes away food particles and remineralizes tooth enamel, providing a lot of natural protection against sugars in our mouths.
GLP-1 drugs can influence salivary gland function and decrease saliva production. They are also known to reduce thirst, further diminishing saliva production.
5 Gingivitis (seen here) is inflammation of the gums, while periodontitis is a more severe form of gum disease.
Dirk – stock.adobe.com
'When the oral environment dries up, bacteria have a great time in there, causing decay and increased inflammatory response,' Walton explained.
'The increased inflammatory response has a direct impact on gingival health — meaning you are more likely to have problems with gingivitis and periodontitis.'
Gingivitis is inflammation of the gums, while periodontitis is a more advanced and destructive form of gum disease.
Dry mouth symptoms can range from mild to rather severe. To avoid having to undergo a painful deep cleaning or gum surgery, Walton's top tip is to drink more water.
She recommends consuming between 2 and 3 liters of H2O a day, which translates to about 64 to 100 ounces. Sugar-free gum also helps promote saliva production.
Biotène, meanwhile, offers a range of products designed to help manage dry mouth symptoms, including a mouth spray, oral rinse, moisturizing gel and lozenges.
5 Walton recommends consuming between 2 and 3 liters of water a day to combat dry mouth.
Stock 4 You – stock.adobe.com
'I found the Biotène gel to be best,' Walton said. 'But I had to carry it with me because the effects only lasted a short period of time.'
GLP-1 users should also avoid dehydrating foods and beverages like caffeinated drinks, alcohol, sports refreshments, salty foods, cured meats, asparagus and sugary juices.
And beware spicy foods, which can irritate a dry mouth.
Battle of the bowl
Another issue with GLP-1 drugs is that they can cause intense gastrointestinal struggles.
'Nausea and vomiting have a massive impact on oral health, just like dry mouth,' Walton said.
'After you vomit, the pH in your mouth decreases significantly enough to make you more susceptible to decay.'
5 Nausea and vomiting are common side effects of GLP-1 drugs like Ozempic.
Dragana Gordic – stock.adobe.com
She suggests not brushing your teeth after you vomit. Yes, you read that right.
Saliva continuously produces a natural protective barrier for your teeth called the dental pellicle.
Brushing your teeth brushes that away, making your teeth even more vulnerable to the newly acidic environment of your mouth.
Acidic substances can be quite harmful, eroding the protective enamel of your teeth and paving the way for increased sensitivity, discoloration and a higher risk of cavities.
'It takes between one to two hours for the pH in your mouth to regain optimal levels after vomiting,' Walton said.
'So, if you get sick, rinse with water,' she added. 'Drink a lot of water — you will be dehydrated anyway because of the medication and now you just puked — and brush your teeth after a couple hours.'
An acquired taste
And finally, GLP-1 drugs can cause changes in taste.
Food may not taste as good as it used to — or the meds leave a metallic or bitter taste in your mouth, which is known as 'Ozempic tongue.'
5 Ozempic and similar drugs can bring major weight loss as well as risky side effects.
Getty Images
'Some of these symptoms will not go away, but luckily, you won't be taking the GLP-1 forever,' Walton said.
The metallic taste may be due to changes in saliva production, mild ketosis or bile reflux. Walton advises sugar-free gum to increase saliva production and 'confuse your brain out of perceiving the metal taste.'
Remember to talk with your healthcare provider about any side effects you experience while taking GLP-1 drugs.
'To be successful in your weight loss, you should enlist as much support as possible,' Walton said. 'Don't forget your dentist! We can help it be easier and safer for you.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 hours ago
- Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis
LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. 'Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,' said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. 'Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. By acting directly in the joint, 4P004 tackles pain, inflammation, and tissue damage through GLP-1-mediated pathways. We believe its targeted intra-articular delivery can unlock the full therapeutic power of GLP-1 biology. We are eager to confirm both symptomatic relief and meaningful structural benefit in this proof-of-concept study'. The study's primary endpoint is the reduction in knee pain at week 4 and 12. Key secondary objectives include assessing synovial changes by contrast-enhanced MRI and conducting an exploratory analysis of blood and imaging biomarkers as potential surrogates for long-term disease progression and delay to total knee replacement. The study timeline covers 12 months, with patient enrollment taking place over 9 months and follow-up to be completed before the topline readout in the second half of 2026. INFLAM MOTION has been designed to generate the first human evidence that 4P004 can deliver both clinical relief and measurable structural benefit. Insights from this Phase 2a readout will shape the forthcoming Phase 2b program, whose primary aim will be to confirm surrogate endpoints that reliably predict the hard endpoint that is delaying the time to total knee replacement. About 4MB Incorporated in mid-2020 as a spin-off of 4P-Pharma, 4MB is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France. Website: LinkedIn: The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.


Newsweek
12 hours ago
- Newsweek
Men Are Gaining More Confidence From Ozempic Than Women: Report
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While some may associate Ozempic and other GLP-1 medications with women trying to lose weight, it turns out that men are the ones gaining the most significant confidence boosts from it. In a Kinsey Institute and survey of GLP-1 users, men were three times more likely than women to say GLP-1s gave them more confidence. They also experienced more notable improvements in their dating lives and libidos. Why It Matters In recent years, the use of weight-loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists has surged. Popular products include Ozempic, Mounjaro, Wegovy and Zephound and have been a game changer for many Americans who are obese or have type 2 diabetes. For patients who successfully lose weight, there can be significant changes in their mental health as well as their personal dating lives, but this impact appears to be more pronounced among male users. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Ozempic is medicine for adults with type 2 diabetes. Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia. Steve Christo - Corbis/Corbis via Getty Images What To Know Across the entire survey sample, drugs like Ozempic were having major effects on users' dating lives. While 59 percent of users said the drugs changed their dating experiences, men experienced a more notable impact on their confidence levels and sex lives, according to the report. Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and increased sexual activity. Still, there were some negative implications for men, of which 60 percent said they feared being judged for using GLP-1s and worried they'd be seen as "less masculine" for doing so. Of all GLP-1 users surveyed, 12 percent said they were going on more dates, and 14 percent said they were getting more matches on dating apps. Meanwhile, a whopping 52 percent reported changes in their sex lives. What People Are Saying Dr. Justin Lehmiller, the Kinsey Institute study lead, said in a statement: "I think there's a very nuanced story to tell here. How these drugs impact your sex life will depend on a variety of factors, including drug dosage and drug type, speed of weight loss, starting and ending weight, and how much you changed your health and fitness habits at the same time." "Sexually speaking, it appears that men are experiencing more positive and more negative impacts of GLP-1 medications." What Happens Next The long-term implications of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones. GLP-1 medications are also associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea, and even stomach paralysis in rare cases.
Yahoo
12 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Announces Expansion To Canada
Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and wellness platform announced plans to expand in Canada by offering generic semaglutide. A nurse in a telehealth platform talking with a patient on video call for consultation. This comes at a time when Novo Nordisk is set to lose its patent protection on Ozempic and Wegovy in Canada for not paying a maintenance fee in 2019. Hims & Hers Health, Inc. (NYSE:HIMS) joins a growing list of companies that are capitalizing on Novo Nordisk's lapsed patent on its GLP-1s. The introduction of generics is a pivotal moment for Canada's healthcare industry. With about two-thirds of adults in the country being overweight or obese, access to treatments has remained elusive for many due to the high costs. Hims & Hers Health, Inc. (NYSE:HIMS) intends to offer generic semaglutide at a significant discount to the currently branded versions, with prices expected to further decrease over time. Hims & Hers Health, Inc. (NYSE:HIMS)'s decision to enter the Canadian market follows the company's acquisition of European telehealth platform, Zava, in June, which will expand its services to France, Germany, and Ireland, and grow its active customer base by approximately 50%. While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best German Stocks to Invest in Now and Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data